The next 10 years for tuberculosis vaccines: Do we have the right plans in place?

Expert Review of Vaccines

Volumn 12, Issue 4, 2013, Pages 443-451

  Meyer, Joel ^a   McShane, Helen ^a  

^a NIHR Biomedical Researcg Centre   (United Kingdom)

Author keywords

clinical; development; knowledge; progress; TB; vaccine

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; LIVE VACCINE; RECOMBINANT VACCINE;

AUXOTROPHIC MUTANT; BACTERIAL IMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNOGENICITY; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VACCINATION;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84875958744     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.19     Document Type: Review

References (54)

1. Calmette A. Preventive vaccination against tuberculosis with BCG. Proc. R. Soc. Med. 24(11), 1481-1490 (1931).
2. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb.) 92(Suppl. 1), S6-13 (2012).
3. Dye C, Williams BG. Eliminating human tuberculosis in the twenty-first century. J. R. Soc. Interface 5(23), 653-662 (2008). (Pubitemid 351589747)
4. Ginsberg AM. A proposed national strategy for tuberculosis vaccine development. Clin. Infect. Dis. 30(Suppl. 3), S233-S242 (2000). (Pubitemid 32250413)
5. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685), 537-544 (1998). (Pubitemid 28319235)
6. Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann SH. Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type cytokine responses. J. Infect. Dis. 204(10), 1573-1584 (2011).
7. McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10(11), 1240-1244 (2004). (Pubitemid 39540442)
8. Minassian AM, Rowland R, Beveridge NE et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 1(2), e000223 (2011).
9. Scriba TJ, Tameris M, Smit E et al. A Phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV-and/or Mycobacterium tuberculosis-infected adults. Am. J. Respir. Crit. Care Med. 185(7), 769-778 (2012).
10. Beveridge NE, Price DA, Casazza JP et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur. J. Immunol. 37(11), 3089-3100 (2007). (Pubitemid 350131288)
11. Abbink P, Lemckert AA, Ewald BA et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81(9), 4654-4663 (2007). (Pubitemid 46668663)
12. Sheehy SH, Duncan CJ, Elias SC et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20(12), 2355-2368 (2012).
13. Aagaard C, Hoang T, Dietrich J et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17(2), 189-194 (2011).
14. Leroux-Roels I, Forgus S, De Boever F et al.; The M72 Study Group. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine doi:10.1016/j. vaccine.2012.05.035 (2012) (Epub ahead of print).
15. Flatz L, Hegazy AN, Bergthaler A et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat. Med. 16(3), 339-345 (2010).
16. Sweeney KA, Dao DN, Goldberg MF et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat. Med. 17(10), 1261-1268 (2011).
17. Martin C, Williams A, Hernandez-Pando R et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24(17), 3408-3419 (2006).
18. Verreck FA, Vervenne RA, Kondova I et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 4(4), e5264 (2009).
19. Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb.) 85(1-2), 29-38 (2005). (Pubitemid 40431313)
20. Walker R. Aeras Global Tuberculosis Vaccine Foundation. A Product Development Partnership for New TB Vaccines. Presented at: HIV Vaccines Trial Network Conference. Washington, DC, USA, 6 May 2010.
21. Kupferschmidt K. Infectious disease. Taking a new shot at a TB vaccine. Science 334(6062), 1488-1490 (2011).
22. Beresford B, Sadoff JC. Update on research and development pipeline: tuberculosis vaccines. Clin. Infect. Dis. 50(Suppl. 3), S178-S183 (2010).
23. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl. 1), S58-S67 (2001). (Pubitemid 32925012)
24. Chiang CY, Riley LW. Exogenous reinfection in tuberculosis. Lancet Infect. Dis. 5(10), 629-636 (2005). (Pubitemid 41383908)
25. Verver S, Warren RM, Beyers N et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care Med. 171(12), 1430-1435 (2005). (Pubitemid 40800517)
26. Dharmadhikari AS, Basaraba RJ, Van Der Walt ML et al. Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb.) 91(4), 329-338 (2011).
27. Henao-Tamayo M, Obregon-Henao A, Ordway DJ, Shang S, Duncan CG, Orme IM. A mouse model of tuberculosis reinfection. Tuberculosis (Edinb.) 92(3), 211-217 (2012).
28. Kagina BM, Abel B, Scriba TJ et al.; other members of the South African Tuberculosis Vaccine Initiative. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182(8), 1073-1079 (2010). specific T-cell cytokine expression including IFN-γ.
29. Pathan AA, Minassian AM, Sander CR et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine 30(38), 5616-5624 (2012).
30. van Dissel JT, Arend SM, Prins C et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28(20), 3571-3581 (2010).
31. Beveridge NE, Fletcher HA, Hughes J et al. A comparison of IFNγ detection methods used in tuberculosis vaccine trials. Tuberculosis (Edinb.) 88(6), 631-640 (2008).
32. Hanekom WA, Dockrell HM, Ottenhoff TH et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med. 5(7), e145 (2008).
33. Berry MP, Graham CM, McNab FW et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466(7309), 973-977 (2010).
34. Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116-125 (2009).
35. Wallis RS, Palaci M, Vinhas S et al. A whole blood bactericidal assay for tuberculosis. J. Infect. Dis. 183(8), 1300-1303 (2001). (Pubitemid 32281574)
36. Worku S, Hoft DF. In vitro measurement of protective mycobacterial immunity: antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guerin. Clin. Infect. Dis. 30(Suppl. 3), S257-S261 (2000). (Pubitemid 32250417)
37. Kampmann B, Tena GN, Mzazi S, Eley B, Young DB, Levin M. Novel human in vitro system for evaluating antimycobacterial vaccines. Infect. Immun. 72(11), 6401-6407 (2004). (Pubitemid 39429490)
38. Silver RF, Li Q, Boom WH, Ellner JJ. Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J. Immunol. 160(5), 2408-2417 (1998). (Pubitemid 28119925)
39. Duncan CJ, Draper SJ. Controlled human blood stage malaria infection: current status and potential applications. Am. J. Trop. Med. Hyg. 86(4), 561-565 (2012).
40. Lillie PJ, Berthoud TK, Powell TJ et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVANP+ M1, in humans. Clin. Infect. Dis. 55(1), 19-25 (2012).
41. Marwick C. Volunteers in typhoid infection study will aid future vaccine development. JAMA 279(18), 1423-1424 (1998). (Pubitemid 28228181)
42. Gunther VJ, Putnak R, Eckels KH et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon γ levels during the acute phase of illness. Vaccine 29(22), 3895-3904 (2011).
43. Minassian AM, Satti I, Poulton ID, Meyer J, Hill AV, McShane H. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J. Infect. Dis. 205(7), 1035-1042 (2012).
44. Ota MO, Odutola AA, Owiafe PK et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci. Transl. Med. 3(88), 88ra56 (2011).
45. Billeskov R, Elvang TT, Andersen PL, Dietrich J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS ONE 7(6), e39909 (2012).
46. Ernst JD, Hanekom W, Hawn T, Kampmann B, Rengarajan J. Meeting report: The International Conference on Human Immunity to Tuberculosis. Tuberculosis (Edinb.) 92(5), 440-444 (2012).
47. Ravishankar N, Gubbins P, Cooley RJ et al. Financing of global health: tracking development assistance for health from to 2007. Lancet 373(9681), 2113-2124 (2009).
48. Raviglione M, Zumla A, Marais B, Horton R, Motsoaledi A. A sustainable agenda for tuberculosis control and research. Lancet 379(9821), 1077-1078 (2012).
49. WHO. Stop TB Partnership Tuberculosis Vaccine Candidates 2011. www.stoptb.org/wg/new-vaccines/assets/ documents/TB%20Vaccine%20Pipeline- rAug%202012.pdf (Accessed October 2012)
50. WHO. Global Tuberculosis Control 2011. www.who.int/tb/publications/ global-report/ 2011/gtbr11-full.pdf (Accessed October 2012)
51. WHO. Millennium Development Goals. www.who.int/topics/millennium- development- goals/diseases/en/index.html (Accessed October 2012)
52. WHO. The Global Plan to Stop TB. www.stoptb.org/assets/documents/global/ plan/TB-GlobalPlanToStopTB2011-2015. pdf (Accessed October 2012)
53. ClinicalTrials.gov. www.clinicaltrials.gov (Accessed October 2012)
54. The Decade of Vaccines Collaboration. www.dovcollaboration.org/about-us (Accessed October 2012)